Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Holding NGNE?
Track your performance easily
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.49 - $74.49
Previous Close$15.33
Volume397.98K
Average Volume (3M)245.58K
Market Cap
$255.95M
Enterprise Value$130.07M
Total Cash (Recent Filing)$138.99M
Total Debt (Recent Filing)$13.12M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 18, 2024EPS Estimate
-$1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding14,854,725
10 Day Avg. Volume861,722
30 Day Avg. Volume245,580
Standard Deviation0.29
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.66
Price to Sales (P/S)276.70
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue140.62
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$55.80Price Target Upside257.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Neurogene News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyNGN-401 demonstrated consistent gains across core clinical domains—hand function, gross motor and communication—with all patients achieving 2-point improvements in CGI-I, deepening over time.
Financial PerformanceThe company's financial position is bolstered by a substantial private placement, extending the cash runway significantly.
Regulatory And SafetyThe U.S. FDA completed a review of the safety data for NGN-401 and allowed Neurogene to proceed with the low-dose level.
Bears Say
Adverse EventsA serious adverse event of hyperinflammatory syndrome was reported in a high-dose patient, highlighting risks associated with higher doses.
Program TerminationNGNE terminated the CLN5 Batten disease program following FDA denial of RMAT designation.
Treatment DiscontinuationThe company decided to discontinue the use of the high dose and does not plan to enroll or dose any additional patients into the high-dose cohort.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.49 and its highest was $74.49 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Nov 18, 2024 which is 4 days ago.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Aug 09, 2024. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$1.05 by -$0.04.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -$1.22.
How many shares outstanding does Neurogene have?
Neurogene has 14,854,725 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.09 in its last earnings report, missing expectations of -$1.05. Following the earnings report the stock price went down -13.068%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 19M.
---
Neurogene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.80 (257.92% Upside)
$55.80 (257.92% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 83.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 43.4%
Last 30 Days ▲ 43.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.13%
12-Months-Change
Fundamentals
Return on Equity
-66.90%
Trailing 12-Months
Asset Growth
83.20%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Month Forecast
Average Price Target
$55.80
▲(257.92% Upside)
Technical Analysis
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-8.76%
reiterated a buy rating 2 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -8.76% per trade.
---